COX-2 promotes metastasis in nasopharyngeal carcinoma by mediating interactions between cancer cells and myeloid-derived suppressor cells

OncoImmunology

Volumn 4, Issue 11, 2015, Pages

  Li, Ze Lei ^a   Ye, Shu Biao ^a   OuYang, Li Yin ^a   Zhang, Han ^a   Chen, Yu Shan ^a   He, Jia ^a   Chen, Qiu Yan ^a   Qian, Chao Nan ^a   Zhang, Xiao Shi ^a   Cui, Jun ^b   Zeng, Yi Xin ^a   Li, Jiang ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

COX 2; myeloid derived suppressor cells; nasopharyngeal carcinoma

Indexed keywords

CYCLOOXYGENASE 2; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 6; TRANSFORMING GROWTH FACTOR BETA;

ANGIOGENESIS; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CELL EXPANSION; CELL INTERACTION; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOCHEMISTRY; LUNG METASTASIS; MOUSE; NASOPHARYNX CARCINOMA; NONHUMAN; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SUPPRESSOR CELL; TUMOR GROWTH; UPREGULATION;

EID: 84941795187     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2015.1044712     Document Type: Article

References (58)

1. S.M.Cao, M.J.Simons, C.N.Qian. The prevalence and prevention of nasopharyngeal carcinoma in China. Chin J Cancer 2011; 30(2):114-9; PMID:21272443; http://dx.doi.org/10.5732/cjc.010.10377
2. M.Y.Chen, R.Jiang, L.Guo, X.Zou, Q.Liu, R.Sun, F.Qiu, Z.J.Xia, H.Q.Huang, L.Zhang et al. Locoregional radiotherapy in patients with distant metastases of nasopharyngeal carcinoma at diagnosis. Chin J Cancer 2013; 32(11):604-13; PMID:24206918; http://dx.doi.org/10.5732/cjc.013.10148
3. J.Li, C.N.Qian, Y.X.Zeng. Regulatory T cells and EBV associated malignancies. Int Immunopharmacol 2009; 9(5):590-2; PMID:19539572; http://dx.doi.org/10.1016/j.intimp.2009.01.015
4. L.S.Young, C.W.Dawson. Epstein-Barr virus and nasopharyngeal carcinoma. Chin J Cancer 2014; 33(12):581-90; PMID:25418193; http://dx.doi.org/10.5732/cjc.014.10197
5. N.M.Berezhnaya. Interaction between tumor and immune system: the role of tumor cell biology. Exp Oncol 2010; 32(3):159-66; PMID:21403611
6. J.Candido, T.Hagemann. Cancer-related inflammation. J Clin Immunol 2013; 33 Suppl 1:S79-84; PMID:23225204; http://dx.doi.org/10.1007/s10875-012-9847-0
7. S.Ostrand-Rosenberg, P.Sinha, D.W.Beury, V.K.Clements. Cross-talk between myeloid-derived suppressor cells (MDSC), macrophages, and dendritic cells enhances tumor-induced immune suppression. Semin Cancer Biol 2012; 22(4):275-81; PMID:22313874; http://dx.doi.org/10.1016/j.semcancer.2012.01.011
8. T.Horikawa, J.Yang, S.Kondo, T.Yoshizaki, I.Joab, M.Furukawa, J.S.Pagano. Twist and epithelial-mesenchymal transition are induced by the EBV oncoprotein latent membrane protein 1 and are associated with metastatic nasopharyngeal carcinoma. Cancer Res 2007; 67(5):1970-8; PMID:17332324; http://dx.doi.org/10.1158/0008-5472.CAN-06-3933
9. V.C.Wong, H.Chen, J.M.Ko, K.W.Chan, Y.P.Chan, S.Law, D.Chua, D.L.Kwong, H.L.Lung, G.Srivastava et al. Tumor suppressor dual-specificity phosphatase 6 (DUSP6) impairs cell invasion and epithelial-mesenchymal transition (EMT)-associated phenotype. Int J Cancer 2012; 130(1):83-95; PMID:21387288; http://dx.doi.org/10.1002/ijc.25970
10. R.X.Li, Z.H.Chen, Z.K.Chen. The role of EPH receptors in cancer-related epithelial-mesenchymal transition. Chin J Cancer 2014; 33(5):231-40; PMID:24103789; http://dx.doi.org/10.5732/cjc.013.10108
11. J.M.Lopez-Novoa, M.A.Nieto. Inflammation and EMT: an alliance towards organ fibrosis and cancer progression. EMBO Mol Med 2009; 1(6–7):303-14; PMID:20049734; http://dx.doi.org/10.1002/emmm.200900043
12. X.Q.Pan. The mechanism of the anticancer function of M1 macrophages and their use in the clinic. Chin J Cancer 2012; 31(12):557-63; PMID:23149314; http://dx.doi.org/10.5732/cjc.011.10433
13. R.B.Prasad, F.J.Hosking, J.Vijayakrishnan, E.Papaemmanuil, R.Koehler, M.Greaves, E.Sheridan, A.Gast, S.E.Kinsey, T.Lightfoot et al. Verification of the susceptibility loci on 7p12.2, 10q21.2, and 14q11.2 in precursor B-cell acute lymphoblastic leukemia of childhood. Blood 2010; 115(9):1765-7; PMID:20042726; http://dx.doi.org/10.1182/blood-2009-09-241513
14. X.Xiang, A.Poliakov, C.Liu, Y.Liu, Z.B.Deng, J.Wang, Z.Cheng, S.V.Shah, G.J.Wang, L.Zhang et al. Induction of myeloid-derived suppressor cells by tumor exosomes. Int J Cancer 2009; 124(11):2621-33; PMID:19235923; http://dx.doi.org/10.1002/ijc.24249
15. C.Zoglmeier, H.Bauer, D.Norenberg, G.Wedekind, P.Bittner, N.Sandholzer, M.Rapp, D.Anz, S.Endres, C.Bourquin. CpG blocks immunosuppression by myeloid-derived suppressor cells in tumor-bearing mice. Clin Cancer Res 2011; 17(7):1765-75; PMID:21233400; http://dx.doi.org/10.1158/1078-0432.CCR-10-2672
16. P.Filipazzi, V.Huber, L.Rivoltini. Phenotype, function and clinical implications of myeloid-derived suppressor cells in cancer patients. Cancer Immunol Immunother 2012; 61(2):255-63; PMID:22120756; http://dx.doi.org/10.1007/s00262-011-1161-9
17. S.Solito, I.Marigo, L.Pinton, V.Damuzzo, S.Mandruzzato, V.Bronte. Myeloid-derived suppressor cell heterogeneity in human cancers. Ann N Y Acad Sci 2014; 1319:47-65; PMID:24965257; http://dx.doi.org/10.1111/nyas.12469
18. T.F.Greten, M.P.Manns, F.Korangy. Myeloid derived suppressor cells in human diseases. Int Immunopharmacol 2011; 11(7):802-7; PMID:21237299; http://dx.doi.org/10.1016/j.intimp.2011.01.003
19. D.I.Gabrilovich, S.Nagaraj. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009; 9(3):162-74; PMID:19197294; http://dx.doi.org/10.1038/nri2506
20. J.E.Talmadge. Pathways mediating the expansion and immunosuppressive activity of myeloid-derived suppressor cells and their relevance to cancer therapy. Clin Cancer Res 2007; 13(18 Pt 1):5243-8; PMID:17875751; http://dx.doi.org/10.1158/1078-0432.CCR-07-0182
21. P.Trikha, W.E.Carson, 3rd. Signaling pathways involved in MDSC regulation. Biochim Biophys Acta 2014; 1846(1):55-65; PMID:24727385; http://dx.doi.org/10.1016/j.bbcan.2014.04.003
22. P.Cheng, C.A.Corzo, N.Luetteke, B.Yu, S.Nagaraj, M.M.Bui, M.Ortiz, W.Nacken, C.Sorg, T.Vogl et al. Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein. J Exp Med 2008; 205(10):2235-49; PMID:18809714; http://dx.doi.org/10.1084/jem.20080132
23. K.Movahedi, M.Guilliams, J.Van den Bossche, R.Van den Bergh, C.Gysemans, A.Beschin, P.De Baetselier, J.A.Van Ginderachter. Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood 2008; 111(8):4233-44; PMID:18272812; http://dx.doi.org/10.1182/blood-2007-07-099226
24. Y.Mao, I.Poschke, E.Wennerberg, Y.Pico de Coana, S.Egyhazi Brage, I.Schultz, J.Hansson, G.Masucci, A.Lundqvist et al. Melanoma-educated CD14+ cells acquire a myeloid-derived suppressor cell phenotype through COX-2-dependent mechanisms. Cancer Res 2013; 73(13):3877-87; PMID:23633486; http://dx.doi.org/10.1158/0008-5472.CAN-12-4115
25. S.Zha, V.Yegnasubramanian, W.G.Nelson, W.B.Isaacs, A.M.De Marzo. Cyclooxygenases in cancer: progress and perspective. Cancer Lett 2004; 215(1):1-20; PMID:15374627; http://dx.doi.org/10.1016/j.canlet.2004.06.014
26. L.R.Howe, A.J.Dannenberg. A role for cyclooxygenase-2 inhibitors in the prevention and treatment of cancer. Semin Oncol 2002; 29(3 Suppl 11):111-9; PMID:12138405; http://dx.doi.org/10.1053/sonc.2002.34063
27. Y.Liu, H.Cai, J.Liu, H.Fan, Z.Wang, Q.Wang, M.Shao, X.Sun, J.Diao, Y.Liu et al. A miR-151 binding site polymorphism in the 3′-untranslated region of the cyclin E1 gene associated with nasopharyngeal carcinoma. Biochem Biophys Res Commun 2013; 432(4):660-5; PMID:23416081; http://dx.doi.org/10.1016/j.bbrc.2013.02.024
28. N.Obermajer, R.Muthuswamy, J.Lesnock, R.P.Edwards, P.Kalinski. Positive feedback between PGE2 and COX2 redirects the differentiation of human dendritic cells toward stable myeloid-derived suppressor cells. Blood 2011; 118(20):5498-505; PMID:21972293; http://dx.doi.org/10.1182/blood-2011-07-365825
29. N.Obermajer, R.Muthuswamy, K.Odunsi, R.P.Edwards, P.Kalinski. PGE(2)-induced CXCL12 production and CXCR4 expression controls the accumulation of human MDSCs in ovarian cancer environment. Cancer Res 2011; 71(24):7463-70; PMID:22025564; http://dx.doi.org/10.1158/0008-5472.CAN-11-2449
30. H.L.Ke, H.P.Tu, H.H.Lin, C.Y.Chai, L.L.Chang, W.M.Li, C.C.Li, Y.C.Lee, H.C.Yeh, W.J.Wu et al. Cyclooxygenase-2 (COX-2) up-regulation is a prognostic marker for poor clinical outcome of upper tract urothelial cancer. Anticancer Res 2012; 32(9):4111-6; PMID:22993369
31. L.Y.Khor, K.Bae, A.Pollack, M.E.Hammond, D.J.Grignon, V.M.Venkatesan, S.A.Rosenthal, M.A.Ritter, H.M.Sandler, G.E.Hanks et al. COX-2 expression predicts prostate-cancer outcome: analysis of data from the RTOG 92-02 trial. Lancet Oncol 2007; 8(10):912-0; PMID:17881290; http://dx.doi.org/10.1016/S1470-2045(07)70280-2
32. K.Uchida, S.Schneider, J.M.Yochim, H.Kuramochi, K.Hayashi, K.Takasaki, D.Yang, K.D.Danenberg, P.V.Danenberg. Intratumoral COX-2 gene expression is a predictive factor for colorectal cancer response to fluoropyrimidine-based chemotherapy. Clin Cancer Res 2005; 11(9):3363-8; PMID:15867236; http://dx.doi.org/10.1158/1078-0432.CCR-04-1650
33. S.L.Loong, J.S.Hwang, H.H.Li, J.T.Wee, S.P.Yap, M.L.Chua, K.W.Fong, T.W.Tan. Weak expression of cyclooxygenase-2 is associated with poorer outcome in endemic nasopharyngeal carcinoma: analysis of data from randomized trial between radiation alone versus concurrent chemo-radiation (SQNP-01). Radiat Oncol 2009; 4:23; PMID:19591688; http://dx.doi.org/10.1186/1748-717X-4-23
34. J.Yu, W.Du, F.Yan, Y.Wang, H.Li, S.Cao, W.Yu, C.Shen, J.Liu, X.Ren. Myeloid-derived suppressor cells suppress antitumor immune responses through IDO expression and correlate with lymph node metastasis in patients with breast cancer. J Immunol 2013; 190(7):3783-97; PMID:23440412; http://dx.doi.org/10.4049/jimmunol.1201449
35. M.G.Lechner, D.J.Liebertz, A.L.Epstein. Characterization of cytokine-induced myeloid-derived suppressor cells from normal human peripheral blood mononuclear cells. J Immunol 2010; 185(4):2273-84; PMID:20644162; http://dx.doi.org/10.4049/jimmunol.1000901
36. B.Toh, X.Wang, J.Keeble, W.J.Sim, K.Khoo, W.C.Wong, M.Kato, A.Prevost-Blondel, J.P.Thiery, J.P.Abastado. Mesenchymal transition and dissemination of cancer cells is driven by myeloid-derived suppressor cells infiltrating the primary tumor. PLoS Biol 2011; 9(9):e1001162; PMID: 21980263; http://dx.doi.org/10.1371/journal.pbio.1001162
37. T.X.Cui, I.Kryczek, L.Zhao, E.Zhao, R.Kuick, M.H.Roh, L.Vatan, W.Szeliga, Y.Mao, D.G.Thomas et al. Myeloid-derived suppressor cells enhance stemness of cancer cells by inducing microRNA101 and suppressing the corepressor CtBP2. Immunity 2013; 39(3):611-21; PMID:24012420; http://dx.doi.org/10.1016/j.immuni.2013.08.025
38. R.B.Schnabel, J.Baumert, M.Barbalic, J.Dupuis, P.T.Ellinor, P.Durda, A.Dehghan, J.C.Bis, T.Illig, A.C.Morrison et al. Duffy antigen receptor for chemokines (Darc) polymorphism regulates circulating concentrations of monocyte chemoattractant protein-1 and other inflammatory mediators. Blood 2010; 115(26):5289-99; PMID:20040767; http://dx.doi.org/10.1182/blood-2009-05-221382
39. X.Chen, E.A.Eksioglu, J.Zhou, L.Zhang, J.Djeu, N.Fortenbery, P.Epling-Burnette, S.Van Bijnen, H.Dolstra, J.Cannon et al. Induction of myelodysplasia by myeloid-derived suppressor cells. J Clin Invest 2013; 123(11):4595-611; PMID:24216507; http://dx.doi.org/10.1172/JCI67580
40. S.M.Centuori, M.Trad, C.J.LaCasse, D.Alizadeh, C.B.Larmonier, N.T.Hanke, J.Kartchner, N.Janikashvili, B.Bonnotte, N.Larmonier et al. Myeloid-derived suppressor cells from tumor-bearing mice impair TGF-beta-induced differentiation of CD4+CD25+FoxP3+ Tregs from CD4+CD25-FoxP3- T cells. J Leukoc Biol 2012; 92(5):987-97; PMID:22891289; http://dx.doi.org/10.1189/jlb.0911465
41. M.Fujita, G.Kohanbash, W.Fellows-Mayle, R.L.Hamilton, Y.Komohara, S.A.Decker, J.R.Ohlfest, H.Okada. COX-2 blockade suppresses gliomagenesis by inhibiting myeloid-derived suppressor cells. Cancer Res 2011; 71(7):2664-74; PMID:21324923; http://dx.doi.org/10.1158/0008-5472.CAN-10-3055
42. C.Bocca, F.Bozzo, S.Cannito, M.Parola, A.Miglietta. Celecoxib inactivates epithelial-mesenchymal transition stimulated by hypoxia and/or epidermal growth factor in colon cancer cells. Mol Carcinog 2012; 51(10):783-95; PMID:21882253; http://dx.doi.org/10.1002/mc.20846
43. A.Kirane, J.E.Toombs, K.Ostapoff, J.G.Carbon, S.Zaknoen, J.Braunfeld, R.E.Schwarz, F.J.Burrows, R.A.Brekken. Apricoxib, a novel inhibitor of COX-2, markedly improves standard therapy response in molecularly defined models of pancreatic cancer. Clin Cancer Res 2012; 18(18):5031-42; PMID:22829202; http://dx.doi.org/10.1158/1078-0432.CCR-12-0453
44. A.Gros, S.Turcotte, J.R.Wunderlich, M.Ahmadzadeh, M.E.Dudley, S.A.Rosenberg. Myeloid cells obtained from the blood but not from the tumor can suppress T-cell proliferation in patients with melanoma. Clin Cancer Res 2012; 18(19):5212-23; PMID:22837179; http://dx.doi.org/10.1158/1078-0432.CCR-12-1108
45. H.Zhang, I.Maric, M.J.DiPrima, J.Khan, R.J.Orentas, R.N.Kaplan, C.L.Mackall. Fibrocytes represent a novel MDSC subset circulating in patients with metastatic cancer. Blood 2013; 122(7):1105-13; PMID:23757729; http://dx.doi.org/10.1182/blood-2012-08-449413
46. A.H.Capietto, S.Kim, D.E.Sanford, D.C.Linehan, M.Hikida, T.Kumosaki, D.V.Novack, R.Faccio. Down-regulation of PLCgamma2-beta-catenin pathway promotes activation and expansion of myeloid-derived suppressor cells in cancer. J Exp Med 2013; 210(11):2257-71; PMID:24127488; http://dx.doi.org/10.1084/jem.20130281
47. F.Chalmin, S.Ladoire, G.Mignot, J.Vincent, M.Bruchard, J.P.Remy-Martin, W.Boireau, A.Rouleau, B.Simon, D.Lanneau et al. Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells. J Clin Invest 2010; 120(2):457-71; PMID:20093776; http://dx.doi.org/10.1172/JCI40483
48. C.P.Verschoor, J.Johnstone, J.Millar, M.G.Dorrington, M.Habibagahi, A.Lelic, M.Loeb, J.L.Bramson, D.M.Bowdish. Blood CD33(+)HLA-DR(-) myeloid-derived suppressor cells are increased with age and a history of cancer. J Leukoc Biol 2013; 93(4):633-7; PMID:23341539; http://dx.doi.org/10.1189/jlb.0912461
49. G.S.Karagiannis, T.Poutahidis, S.E.Erdman, R.Kirsch, R.H.Riddell, E.P.Diamandis. Cancer-associated fibroblasts drive the progression of metastasis through both paracrine and mechanical pressure on cancer tissue. Mol Cancer Res 2012; 10(11):1403-18; PMID:23024188; http://dx.doi.org/10.1158/1541-7786
50. A.Facciabene, G.T.Motz, G.Coukos. T-regulatory cells: key players in tumor immune escape and angiogenesis. Cancer Res 2012; 72(9):2162-71; PMID:22549946; http://dx.doi.org/10.1158/0008-5472.CAN-11-3687
51. J.Fuxe, M.C.Karlsson. TGF-beta-induced epithelial-mesenchymal transition: a link between cancer and inflammation. Semin Cancer Biol 2012; 22(5-6):455-61; PMID:22627188; http://dx.doi.org/10.1016/j.semcancer.2012.05.004
52. T.Lu, R.Ramakrishnan, S.Altiok, J.I.Youn, P.Cheng, E.Celis, V.Pisarev, S.Sherman, M.B.Sporn, D.Gabrilovich. Tumor-infiltrating myeloid cells induce tumor cell resistance to cytotoxic T cells in mice. J Clin Invest 2011; 121(10):4015-29; PMID:21911941; http://dx.doi.org/10.1172/JCI45862
53. A.Qin, W.Cai, T.Pan, K.Wu, Q.Yang, N.Wang, Y.Liu, D.Yan, F.Hu, P.Guo, X.Chen et al. Expansion of monocytic myeloid-derived suppressor cells dampens T cell function in HIV-1-seropositive individuals. J Virol 2012; 87(3):1477-90; PMID:23152536; http://dx.doi.org/10.1128/JVI.01759-12
54. R.Du, C.Huang, Q.Bi, Y.Zhai, L.Xia, J.Liu, S.Sun, D.Fan. URG11 mediates hypoxia-induced epithelial-to-mesenchymal transition by modulation of E-cadherin and beta-catenin. Biochem Biophys Res Commun 2010; 391(1):135-41; PMID:19900406; http://dx.doi.org/10.1016/j.bbrc.2009.11.019
55. S.Y.Lee, H.M.Jeon, M.K.Ju, C.H.Kim, G.Yoon, S.I.Han, H.G.Park, H.S.Kang. Wnt/Snail signaling regulates cytochrome C oxidase and glucose metabolism. Cancer Res 2012; 72(14):3607-17; PMID:22637725; http://dx.doi.org/10.1158/0008-5472.CAN-12-0006
56. R.A.Soo, J.Wu, A.Aggarwal, Q.Tao, W.Hsieh, T.Putti, K.B.Tan, J.S.Low, Y.F.Lai, B.Mow et al. Celecoxib reduces microvessel density in patients treated with nasopharyngeal carcinoma and induces changes in gene expression. Ann Oncol 2006; 17(11):1625-30; PMID:17008411; http://dx.doi.org/10.1093/annonc/mdl283
57. W.P.Xue, S.M.Bai, M.Luo, Z.F.Bi, Y.M.Liu, S.K.Wu. Phase I clinical trial of nasopharyngeal radiotherapy and concurrent celecoxib for patients with locoregionally advanced nasopharyngeal carcinoma. Oral Oncol 2011; 47(8):753-7; PMID:21708478; http://dx.doi.org/10.1016/j.oraloncology.2011.06.002
58. J.He, X.F.Tang, Q.Y.Chen, H.Q.Mai, Z.F.Huang, J.Li, Y.X.Zeng. Ex vivo expansion of tumor-infiltrating lymphocytes from nasopharyngeal carcinoma patients for adoptive immunotherapy. Chin J Cancer 2012; 31(6):287-94; PMID:22257383; http://dx.doi.org/10.5732/cjc.011.10376